slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 76,201-76,230
Pages 3,679
Rows per page 30
Component
76,201-76,230 of 110,355
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a timeline-based framework to contrast current treatment options with clinical unmet needs.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes clinical trial data from ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Data as of 13 Sep 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The slide uses a comparative framework to highlight unmet needs in 2L+ and the potential for market leadership in 1L.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
Includes three distinct preclinical assay results: In Vitro Activity, Selectivity Index, and Brain Penetrance.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a table-like structure to represent a clinical trial roadmap, incorporating regulatory designations and partner logos.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
08
The slide presents experimental evidence (Western blot) supporting the mechanism of action for NXP800 in ARID1a-deficient cancer cells.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Includes two line charts showing tumor volume reduction over time and a table showing patient incidence for target indications.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study methodology diagram and a line chart showing tumor volume over time.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
The slide uses a patient selection strategy based on ARID1a mutation status.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
13
The slide uses a split-column layout to contrast two phases of a clinical trial.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
The charts are kinome dendrograms (KinomeScan style).Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Voice Of Customer1 hit
18
Includes a biological pathway diagram and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Voice Of Customer1 hit
20
Includes two distinct experimental setups: in vitro proliferation assays and in vivo bioluminescence imaging (BLI) tumor growth studies.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
21
The table segments indications by Squamous cell prevalence and NF2 mutation prevalence.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
08
Oscar Health | Investor Conference Presentation Deck | 9 slidesOscar Health | Investor Conference Presentation Deck | 9 slides · Oscar Health
Conference presentation Investor relations Beat · Ultimate AchievementLoop · Quick Win Big Bet1 hit
09
The chart shows a clear downward trend in medical costs for all cohorts compared to the rising benchmark.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
11
Includes IBNR for YTD Q3'23; excludes ACO Reach; represents MA only.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Loop · Hypothesis Test1 hit
16
The chart shows a bridge from $(128)M in 2022 to $30M in 2024G.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
03
Pathward Financial | Results Presentation Deck | 34 slidesPathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle1 hit
06
The slide uses a consistent color scheme (light blue for Q1 2023, dark blue for Q1 2024) and percentage change callouts for each metric.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a numbered list format to present financial assumptions.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Golden Circle1 hit
14
Includes adjustments for one-time items and 1st quarter earnings breakdowns.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
15
Includes a disclaimer note regarding share repurchases.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
17
Includes a detailed income statement table and bulleted commentary on revenue and expense drivers.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
19
The slide uses a combination of a pie chart for composition and a stacked bar chart for historical growth trends.Pathward Financial | Results Presentation Deck | 34 slides · Pathward Financial
Conference presentation Investor relations Beat · Market Size1 hit